个人中心 - 老虎社区

Zenithtan

IP属地：未知

帖子 · 5帖子 · 5
关注 · 0关注 · 0
粉丝 · 0粉丝 · 0

- ZenithtanZenithtan
  ·2021-06-18
  [Cry]
  非常抱歉，此主贴已删除
  359 评论
  点赞
  分享
  举报
- ZenithtanZenithtan
  ·2021-06-18
  [Cool] [Cool]
  非常抱歉，此主贴已删除
  1,454 评论
  2
  分享
  举报
- ZenithtanZenithtan
  ·2021-06-18
  ohh..
  Low dosage may be behind low efficacy of CureVac vaccine: Study leader
  BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa
  Low dosage may be behind low efficacy of CureVac vaccine: Study leader
  630 评论
  点赞
  分享
  举报
- ZenithtanZenithtan
  ·2021-06-18
  😭
  非常抱歉，此主贴已删除
  642 评论
  点赞
  分享
  举报
- ZenithtanZenithtan
  ·2021-06-18
  hmm
  RUN Stock: Why Morgan Stanley Thinks Sunrun Is the ‘Most Compelling’ Clean Energy Stock
  Sunrun(NASDAQ:RUN) stock is running higher on Thursday following a positive report on the company fr
  RUN Stock: Why Morgan Stanley Thinks Sunrun Is the ‘Most Compelling’ Clean Energy Stock
  1,660 评论
  2
  分享
  举报
暂无粉丝

热议股票

{"i18n":{"language":"zh_CN"},"isCurrentUser":false,"userPageInfo":{"id":"3584434944941333","uuid":"3584434944941333","gmtCreate":1621341728534,"gmtModify":1621341728534,"name":"Zenithtan","pinyin":"zenithtan","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":3,"tweetSize":5,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":1,"name":"萌萌虎","nameTw":"萌萌虎","represent":"呱呱坠地","factor":"评论帖子3次或发布1条主帖（非转发）","iconColor":"3C9E83","bgColor":"A2F1D9"},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":null,"userBadges":[{"badgeId":"e50ce593bb40487ebfb542ca54f6a561-1","templateUuid":"e50ce593bb40487ebfb542ca54f6a561","name":"出道虎友","description":"加入老虎社区500天","bigImgUrl":"https://static.tigerbbs.com/0e4d0ca1da0456dc7894c946d44bf9ab","smallImgUrl":"https://static.tigerbbs.com/0f2f65e8ce4cfaae8db2bea9b127f58b","grayImgUrl":"https://static.tigerbbs.com/c5948a31b6edf154422335b265235809","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2022.10.02","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"518b5610c3e8410da5cfad115e4b0f5a-1","templateUuid":"518b5610c3e8410da5cfad115e4b0f5a","name":"实盘交易者","description":"完成一笔实盘交易","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":2,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":1,"crmLevelSwitch":0,"location":"未知","starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":168308600,"gmtCreate":1623948682000,"gmtModify":1634025348937,"author":{"id":"3584434944941333","authorId":"3584434944941333","name":"Zenithtan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584434944941333","idStr":"3584434944941333"},"themes":[],"htmlText":"[Cry]&nbsp;","listText":"[Cry]&nbsp;","text":"[Cry]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168308600","repostId":"2144449657","repostType":2,"isVote":1,"tweetType":1,"viewCount":359,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168972418,"gmtCreate":1623948376934,"gmtModify":1634025356218,"author":{"id":"3584434944941333","authorId":"3584434944941333","name":"Zenithtan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584434944941333","idStr":"3584434944941333"},"themes":[],"htmlText":"[Cool]&nbsp;[Cool]&nbsp;","listText":"[Cool]&nbsp;[Cool]&nbsp;","text":"[Cool] [Cool]","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168972418","repostId":"2144411077","repostType":4,"isVote":1,"tweetType":1,"viewCount":1454,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168976215,"gmtCreate":1623948340737,"gmtModify":1634025356822,"author":{"id":"3584434944941333","authorId":"3584434944941333","name":"Zenithtan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584434944941333","idStr":"3584434944941333"},"themes":[],"htmlText":"ohh..","listText":"ohh..","text":"ohh..","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168976215","repostId":"2144744636","repostType":4,"repost":{"id":"2144744636","kind":"news","pubTimestamp":1623940250,"share":"https://www.laohu8.com/m/news/2144744636?lang=&edition=full","pubTime":"2021-06-17 22:30","market":"sg","language":"en","title":"Low dosage may be behind low efficacy of CureVac vaccine: Study leader","url":"https://stock-news.laohu8.com/highlight/detail?id=2144744636","media":"The Straits Times","summary":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disa","content":"<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n","source":"straits_highlight","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Low dosage may be behind low efficacy of CureVac vaccine: Study leader</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLow dosage may be behind low efficacy of CureVac vaccine: Study leader\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 22:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader><strong>The Straits Times</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said ...</p>\n\n<a href=\"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"CVAC":"CureVac B.V."},"source_url":"http://www.straitstimes.com/world/europe/low-dosage-may-be-behind-low-efficacy-of-curevac-vaccine-study-leader","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2144744636","content_text":"BERLIN (REUTERS) - The low dosage might be a key reason why CureVac's Covid-19 vaccine reported disappointing efficacy in a pivotal late-stage trial, the scientist leading the study of the shot said on Thursday (June 17).\nThe German biotech's vaccine proved only 47 per cent effective in an initial trial, far lower than those of rivals BioNTech/Pfizer and Moderna, which are also based on mRNA technology and had efficacy rates well above 90 per cent.\nDr Peter Kremsner from the University Hospital in Tuebingen which is running the trial, told Reuters the low efficacy is \"very likely due to the dose\".\nUnlike BioNTech and Moderna, CureVac did not modify the mRNA used in the shots and therefore a higher dosage was not possible because of the side effects to be expected, Dr Kremsner said.\nWith just 12 micrograms of mRNA per dose, the company has been seeking to position itself as a low-dose alternative to BioNTech and Moderna's established shots with 30 and 100 micrograms per shot, respectively.\nIt is also easy to store and cheaper than the other mRNA shots too.\nThe European Union has agreed to pay 12 euros (S$19.20) per dose for supplies of the shot, an EU internal document shows, but has paid more than 15 euros for the other mRNA shots.\nHowever, the interim trial analysis goes some way to challenging the expectation, which was previously reflected in the company's share price, that all mRNA vaccines are similar.\nThe news wiped as much as 52 per cent off the company's value on Thursday.\nCureVac said on Wednesday that new variants had proved a headwind, but data from BioNTech and Moderna have, however, so far suggested only somewhat weaker protection against new variants.\nDr Kremsner said he thought it was probably a \"long shot\" as to whether CureVac's vaccine might turn out to be more effective when targeting a particular variant.\nThe disappointing results are a blow since European governments had been hoping to add it to their arsenal after age limits were imposed on the use of the Johnson & Johnson and AstraZeneca vaccines due to a link to extremely rare but potentially fatal clotting disorders.","news_type":1,"symbols_score_info":{"CVAC":0.9}},"isVote":1,"tweetType":1,"viewCount":630,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168978125,"gmtCreate":1623948299867,"gmtModify":1634025358094,"author":{"id":"3584434944941333","authorId":"3584434944941333","name":"Zenithtan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584434944941333","idStr":"3584434944941333"},"themes":[],"htmlText":"😭","listText":"😭","text":"😭","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168978125","repostId":"2144426397","repostType":4,"isVote":1,"tweetType":1,"viewCount":642,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":168973584,"gmtCreate":1623948255948,"gmtModify":1634025359296,"author":{"id":"3584434944941333","authorId":"3584434944941333","name":"Zenithtan","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":1,"crmLevelSwitch":0,"followedFlag":false,"authorIdStr":"3584434944941333","idStr":"3584434944941333"},"themes":[],"htmlText":"hmm","listText":"hmm","text":"hmm","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/168973584","repostId":"1100514296","repostType":4,"repost":{"id":"1100514296","kind":"news","pubTimestamp":1623943229,"share":"https://www.laohu8.com/m/news/1100514296?lang=&edition=full","pubTime":"2021-06-17 23:20","market":"us","language":"en","title":"RUN Stock: Why Morgan Stanley Thinks Sunrun Is the ‘Most Compelling’ Clean Energy Stock","url":"https://stock-news.laohu8.com/highlight/detail?id=1100514296","media":"investorplace","summary":"Sunrun(NASDAQ:RUN) stock is running higher on Thursday following a positive report on the company fr","content":"<p><b>Sunrun</b>(NASDAQ:<b><u>RUN</u></b>) stock is running higher on Thursday following a positive report on the company from Morgan Stanley.</p>\n<p>Morgan Stanley analyst Stephen Byrd isbehind the newsboosting RUN stock up. In his report, he reiterated the firm’s overweight rating while also increasing the price target to $91. The previous price target MS had for the stock was $86.</p>\n<p>So what has Byrd taking such a bullish stance on RUN stock? First off, he believes that there’s massive potential for the growth of the company. That centers on the adoption of solar panels to power homes. Currently, only 3% of homes in the U.S. are equipped with solar panels.</p>\n<p>It’s not just the potential of solar homes that has the Morgan Stanley analyst taking this stance on RUN stock. The possibility of its technology being used alongside electric vehicles (EVs) also shows promise.</p>\n<p>Sunrun has already been dipping its toes into this space as it teams up with<b>Ford</b>(NYSE:<b><u>F</u></b>) on the company’sF-150 Lightning electric truck. It supplies solar panels to charge the truck at home, as well as a kit that lets the truck power the house when the electricity is out. These factors are what has Byrd calling RUN “the most compelling clean energy stock,” reports<i>CNBC</i>.</p>\n<p>The bull report on RUN stock has it seeing heavy trading today. As of this writing, more than 10 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is roughly 6.2 million shares.</p>\n<p>RUN stock was up 10.2% as of Thursday morning but is down 24.5% since the start of the year.</p>\n<p>Of course, there’s plenty of other news for today that investors should keep up with.</p>","source":"lsy1606302653667","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>RUN Stock: Why Morgan Stanley Thinks Sunrun Is the ‘Most Compelling’ Clean Energy Stock</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nRUN Stock: Why Morgan Stanley Thinks Sunrun Is the ‘Most Compelling’ Clean Energy Stock\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-06-17 23:20 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://investorplace.com/2021/06/run-stock-why-morgan-stanley-thinks-sunrun-is-the-most-compelling-clean-energy-stock/><strong>investorplace</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sunrun(NASDAQ:RUN) stock is running higher on Thursday following a positive report on the company from Morgan Stanley.\nMorgan Stanley analyst Stephen Byrd isbehind the newsboosting RUN stock up. In ...</p>\n\n<a href=\"https://investorplace.com/2021/06/run-stock-why-morgan-stanley-thinks-sunrun-is-the-most-compelling-clean-energy-stock/\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://investorplace.com/2021/06/run-stock-why-morgan-stanley-thinks-sunrun-is-the-most-compelling-clean-energy-stock/","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1100514296","content_text":"Sunrun(NASDAQ:RUN) stock is running higher on Thursday following a positive report on the company from Morgan Stanley.\nMorgan Stanley analyst Stephen Byrd isbehind the newsboosting RUN stock up. In his report, he reiterated the firm’s overweight rating while also increasing the price target to $91. The previous price target MS had for the stock was $86.\nSo what has Byrd taking such a bullish stance on RUN stock? First off, he believes that there’s massive potential for the growth of the company. That centers on the adoption of solar panels to power homes. Currently, only 3% of homes in the U.S. are equipped with solar panels.\nIt’s not just the potential of solar homes that has the Morgan Stanley analyst taking this stance on RUN stock. The possibility of its technology being used alongside electric vehicles (EVs) also shows promise.\nSunrun has already been dipping its toes into this space as it teams up withFord(NYSE:F) on the company’sF-150 Lightning electric truck. It supplies solar panels to charge the truck at home, as well as a kit that lets the truck power the house when the electricity is out. These factors are what has Byrd calling RUN “the most compelling clean energy stock,” reportsCNBC.\nThe bull report on RUN stock has it seeing heavy trading today. As of this writing, more than 10 million shares of the stock have changed hands. To put that in perspective, the company’s daily average trading volume is roughly 6.2 million shares.\nRUN stock was up 10.2% as of Thursday morning but is down 24.5% since the start of the year.\nOf course, there’s plenty of other news for today that investors should keep up with.","news_type":1,"symbols_score_info":{"RUN":0.9}},"isVote":1,"tweetType":1,"viewCount":1660,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"followers","isTTM":false}